Background and study aim: : Chronic hepatitis B (CHB) is a long term liver infection caused by the Heaptis B Virus (HBV) that lasts for more than sex months. Which is a critical worldwide health issue, often resulting in hepatic cirrhosis, fibrosis, and hepatocellular cancercinmo. Early recognition of hepatic fibrosis is critical for preventing illness progression. The aim of this research is to evaluate the role of platelet indices (Platelet Count, Mean Platelet Volume (MPV), Platelet Distribution Width (PDW), and Plateletcrit (PCT)) in detecting the extent of liver fibrosis in CHB cases and to compare their diagnostic value with FIB-4 and APRI scores,Patients and Methods: This descriptive cross-sectional study was conducted at the Internal Medicine outpatient clinic of Assiut University Hospital from October 2022 to January 2024, involving 73 patients aged 18–70 years with chronic hepatitis B (HBsAg positive for over six months),Results: Platelet count and PCT significantly decreased as fibrosis progressed, while MPV showed an increasing trend. APRI and FIB-4 scores increased with advanced fibrosis stages. At a platelet count cut-off ≤209 ×10⁹/L, the sensitivity and specificity for expecting fibrosis were 88.2% and 90.9%, correspondingly. APRI and FIB-4 demonstrated excellent diagnostic accuracy, with areas under the curve (AUC) of 0.990 and 0.983, correspondingly.Conclusion: Platelet indices, particularly platelet count and MPV, are valuable non-invasive indicators for identifying hepatic fibrosis in CHB cases. In combination with APRI and FIB-4, they offer a good non invasive alternatives to liver biopsy for fibrosis assessment, particularly in resource-limited settings.
Maghraby et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: